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 On behalf of the authors of [1].To the Editor:
We are grateful to Drs. Bruno and Mangia for their interest in our 
work [1], and we agree that data on response rates by the degree 
of ﬁbrosis would be useful and would help guide physician s and 
patients in reaching a decision regarding the value of therapy, fol- 
lowing a ‘lead-in’ phase. However, in a retrospec tive analysis of
study subpopulat ions in a trial that was not designed, or pow- 
ered, to answer the question of interest, there is a difﬁcult line 
to be drawn between an ‘appropri ate analysis’ and ‘data dredg- 
ing’. The REALIZE study [2] was powered to investigat e the value 
of telaprevir in patients who had failed to respond to pegylate d
interferon and ribavirin and was designed to include a study 
arm examinin g the value of a ‘lead in’ with pegylated interferon 
and ribavirin. Only half of the enrolled patients therefore received 
a ‘lead-in’ reducing the number of subjects whose response to
pegylated interferon and ribavirin could be assessed . We believe 
that a retrospec tive analysis of patients divided by prior treat- 
ment response and response during ‘lead-in’ is appropriat e, but 
to sub-divid e the population further is, in our view, an analysis 
too far. The number of null-respond er patients with cirrhosis 
who responded during the lead in phase was 7 – in our view to
quote response rates following telaprevir based on such a small 
number of patients is of limited value and is potential ly harmful 
– clinicians and patients should not be encourag ed to base their 
treatment decisions on subset analyses with very wide conﬁ-
dence interval s, as such decisions are likely to be incorrect. We
recognize that studies with other drugs where all patien ts receive 
a lead-in may recruit sufﬁcient patients for a meaningf ul analysis,1260 Journal of Hepatology 20but for telaprevir where the ‘lead in’ is optional and for the REAL- 
IZE study, where only half of the patients received a ‘lead in’, we
believe that further sub-analy ses are not appropriate. We accept 
that others would take a differen t approach to the data and we
accept that the desire for data sometimes overrides the desire 
for informa tive data. Howeve r, we do not believe that publicati on
of results from very small subsets of patients should be
encouraged.Conﬂict of interes t
Consultancy work and advisary boards for Janssen, Roche, Merck,
Gilead, Novartis, BI and BMS.Response asse ssment methodologies in hepa tocellular 
carcino ma: Compl exities in the era of local and system ic treatme nts To the Editor:
Although the mainstay of hepatocell ular carcinoma (HCC) treat- 
ment has been locoregiona l, new systemic agents have demon- 
strated signiﬁcant improvem ent in time-to-pro gression (TTP)
and survival, leading some to postulate TTP as a surrogate of sur- 
vival. While there is some rationale supportin g this concept in
advanced disease, complexi ties in HCC imaging should temper 
expanding this enthusiasm to early/int ermediate disease until 
more robust evidence is available. Several examples of this lack 
of correlation exist in the radiofrequen cy ablation (RFA), chemo- 
embolizatio n (TACE)/radioembolizat ion, and systemic therapy 
literature. Although we agree with EASL-EORTC guidelines that 
mRECIST helps move the ﬁeld forward, several imaging complex- 
ities remain unaddressed [1,2]. These were highlighted by our 
core imaging research group following a formal review of 463 
HCC patients (1818 scans) treated with chemoe mbolizatio n/
radioemboliz ation [3,4].13The ﬁrst imaging complexi ty relates to arterial embolic thera- 
pies. Since these are performed at staged interval s, imaging fol- 
low-up involves the simulta neous radiologic interpr etation of
treated/unt reated disease. This creates difﬁculty in assessing 
response; should response only be measured in the treated 
lesion(s)? How should untreated targets be considered if they 
have sufﬁciently enlarged to meet progressive disease criteria? 
Should imaging only be assessed when all tumors have been trea- 
ted and if so, how should patients never completin g all treat- 
ments (toxicities/decompen sation) be reported? [5,6]. These 
methodologi cal nuances are under-re ported in locoregio nal ther- 
apy studies. Accurately assessing response/p rogression (or lack 
thereof) in the liver is critical since HCC progression is predomi -
nantly local [7]. This is also of importan ce since it suggests that 
the clinical sequela e of progression may be depende nt on the 
treatment received (see Clinical scenarios, Supplem entary infor- 
mation). These concepts further suggest that new (automated)vol. 58 j 1258–1266
